ARTV · Stock research · Public disclosure research

ARTV — Artiva Biotherapeutics, Inc.: Insider & Congressional Trading Activity

Data as of Nov 18, 2026. Collected disclosures, not exhaustive history.

30-day and 12-month windows end Nov 22, 2026 and use transaction dates, not disclosure dates. The data-as-of date above reflects the latest collected disclosure and may be older than the window end.

Insider buys · 30d0Collected open-market purchases
Insider sales · 30d9Collected sales
Net reported value · 30d-$987,430.00Reported purchase value less reported sale value, trailing 30 days.
Congressional trades · 12m0By trade date; latest collected disclosure: —
Latest filing on recordForm 4Filed Nov 18, 2026

For transactions dated in the 30-day window ending Nov 22, 2026, collected disclosures for Artiva Biotherapeutics, Inc. (ARTV) show 9 sales by insiders. Net reported purchase less sale value is -$987,430.00.

Short-interest snapshot

View settlement history →
Short interest · shares2,296,734Settlement: Sep 30, 2026
SI % · shares outstanding—Settlement: Sep 30, 2026
Days to cover3.67 daysSettlement: Sep 30, 2026
Change · shares+231,584Settlement: Sep 30, 2026Prior settlement: Sep 15, 2026
Change · percent+11.2139%Settlement: Sep 30, 2026Prior settlement: Sep 15, 2026

FINRA short interest via Polygon. Updated Oct 12, 2026. Changes compare the displayed settlement with the prior settlement, not daily trading activity.

SI % uses shares outstanding available at enrichment time, not historical shares-outstanding counts. It is not a percentage of float. Missing percentages remain not reported; no shares-outstanding lookup is performed on page render.

Recent insider transactions

View all insider transactions →
Up to five collected transactions, prioritizing open-market purchases and sales. Open-market purchases and sales appear first by default, newest first within each group. Values are reported, not estimates. Derivative transactions are labeled separately.
Bush JenniferCOO, CLO, Compliance OfficerOpen-market saleNon-derivative security10b5-1: —19,217$3.91$75,175.00338,503Nov 17, 2026Nov 18, 2026Source record
Horan ChristopherChief Tech Operations OfficerOpen-market saleNon-derivative security10b5-1: —20,546$3.91$80,374.00281,775Nov 17, 2026Nov 18, 2026Source record
Miralles Gines DiegoPresident & Head of R&DOpen-market saleNon-derivative security10b5-1: —1,043$3.91$4,080.00121,457Nov 17, 2026Nov 18, 2026Source record
Aslan FredCEOOpen-market saleNon-derivative security10b5-1: —119,771$3.91$468,532.001,337,657Nov 17, 2026Nov 18, 2026Source record
Banerjee SubhashisChief Medical OfficerOpen-market saleNon-derivative security10b5-1: —4,037$3.91$15,792.00164,701Nov 17, 2026Nov 18, 2026Source record

Read the disclosure, then the context

Insider data covers the trailing 12 months on public tables. Congressional tables cover all saved disclosures. Neither is an exhaustive history. Form 4 filing dates and congressional disclosure dates may differ from trade dates. Congressional amounts are ranges, not estimated dollar totals. Disclosure activity alone does not establish intent or predict returns.

From disclosure to research

Keep ARTV on your research desk.

Create a workspace for filing analysis and research notes. Filing-alert availability depends on your plan. Review the plan features separately; opening the plans page does not create an alert.